Liver function in children with human immunodeficiency virus infection before and after 6 months of highly active antiretroviral therapy
Background Highly active antiretroviral therapy (HAART) has resulted in dramatic decreases in morbidity and improved survival rate in human immunodeficiency virus (HIV)-infected patients. Although the risk of morbidity has decreased, it has been replaced by other long-term complications, such as hep...
Saved in:
Published in | Paediatrica Indonesiana Vol. 58; no. 4; pp. 159 - 64 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Indonesian Pediatric Society Publishing House
01.07.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background Highly active antiretroviral therapy (HAART) has resulted in dramatic decreases in morbidity and improved survival rate in human immunodeficiency virus (HIV)-infected patients. Although the risk of morbidity has decreased, it has been replaced by other long-term complications, such as hepatotoxicity. Hepatotoxicity is often reflected in biochemical abnormalities of liver function, such as elevated levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and aspartate aminotransferase-to-platelet ratio index (APRI).
Objective To compare liver function spectrum (AST, ALT, and APRI) in HIV-infected children before and after at least 6 months of HAART.
Methods This observational study (before and after) was conducted in pediatric patients with HIV infection who received HAART for at least 6 months at Sanglah Hospital, Denpasar. Data were collected from medical records.
Results Forty-nine patients were observed in this study. The mean AST, ALT, and APRI levels before HAART were higher than after at least 6 months of HAART. Anti-tuberculosis treatment and fluconazole therapy were not confounding factors for AST, ALT, and APRI.
Conclusion Liver function spectrum enzyme levels of AST, ALT, and APRI are improved after at least 6 months of HAART. |
---|---|
ISSN: | 0030-9311 2338-476X |
DOI: | 10.14238/pi58.4.2018.159-64 |